Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

SIMPLE SUMMARY: Ramucirumab is indicated at a dosage of 8 mg/kg every 2 weeks as monotherapy or in combination with paclitaxel for second-line advanced/metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. A post hoc analysis of the phase III trials REGARD and RAINBOW suggested a positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Manish A., Udrea, Anghel Adrian, Bondarenko, Igor, Mansoor, Was, Sánchez, Raquel Guardeño, Sarosiek, Tomasz, Bozzarelli, Silvia, Schenker, Michael, Gomez-Martin, Carlos, Morgan, Carys, Özgüroğlu, Mustafa, Pikiel, Joanna, Kalofonos, Haralabos P., Wojcik, Elzbieta, Buchler, Tomas, Swinson, Daniel, Cicin, Irfan, Joseph, Mano, Vynnychenko, Ihor, Luft, Alexander Valerievich, Enzinger, Peter C., Salek, Tomas, Papandreou, Christos, Tournigand, Christophe, Maiello, Evaristo, Wei, Ran, Ferry, David, Gao, Ling, Oliveira, Joana M., Ajani, Jaffer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909008/
https://www.ncbi.nlm.nih.gov/pubmed/35267477
http://dx.doi.org/10.3390/cancers14051168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909008/
https://www.ncbi.nlm.nih.gov/pubmed/35267477
http://dx.doi.org/10.3390/cancers14051168

Ejemplares similares